当前位置: 首页 >> 检索结果
1. [Systematic review and Meta-analysis on chemotherapy-induced bone marrow suppression treated with acupuncture].
作者: Rui Huang.;Tong Li.;Mei-Xia Li.;Si-Ting Ye.;Na Nie.;Yi Liang.
来源: Zhongguo Zhen Jiu. 2021年41卷5期557-62页
To review systematically the effectiveness of acupuncture in treatment of chemotherapy-induced bone marrow suppression.
2. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Immune checkpoint inhibitors (ICIs) have good efficacy on most advanced tumors, which brings new hope to patients with advanced tumors. However, the immune system activated by ICIs may attack human normal tissues and organs, resulting in corresponding immunotoxicity, such as checkpoint inhibitor pneumonitis. This article carried out a meta-analysis on the incidence and risk of programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitor-associated pneumonia in advanced tumors patients.
3. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review].
In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently reported due to its specificity and severity. This article is to summarize and evaluate ir-AEs induced by ICIs. Hopefully it can provide guidance for advanced NSCLC patients treatment options, early recognition and management of ir-AEs.
4. [A Meta-Analysis of Efficacy and Adverse Effects of Lobaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion].
作者: Shihui Min.;Qiangqiang Zheng.;Bailu Zhang.;Danli Yan.;Rulan Wang.;Zihan Qu.;Lu Li.;Jiewei Liu.;Qinghua Zhou.
来源: Zhongguo Fei Ai Za Zhi. 2019年22卷2期90-98页
The aim of this study is to systematically evaluate the efficacy and adverse effects of Lobaplatin and Cisplatin in the treatment of malignant pleural effusion.
5. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
The combination therapy of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has attracted the attention of more and more investigators. The aim of this meta-analysis is to evaluate the clinical efficacy and safety of intercalated combination of chemotherapy and EGFR- TKIs versus chemotherapy alone in the first-line therapy of advanced non-small cell lung cancer (NSCLC).
6. [Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].
作者: Tao Zhang.;Shuaifei Yuan.;Ziping Wang.;Qian Zhang.;Panpan Zhao.;Li Shan.
来源: Zhongguo Fei Ai Za Zhi. 2013年16卷2期82-90页
Bevacizumab is a recombinant, humanised, monoclonal antibody against the vascular endothelial growth factor receptor (VEGFR), the aim of this meta-analysis is to evaluate the clinical efficacy and safety of bevacizumab combined with chemotherapy for non-small cell lung cancer (NSCLC).
7. [A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer].
作者: Chong'an Xu.;Ziyou Chang.;Xiaojie Wang.;Lin Li.;Haiyan Qi.;Yan Liu.
来源: Zhongguo Fei Ai Za Zhi. 2012年15卷6期361-8页
It remains disputed whether doublets are more effective than single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy and safety of doublets and single-agent chemotherapy for elderly patients with NSCLC.
8. [Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
Vandetanib is a small molecule inhibitor against vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). The aim of this study is to evaluate the efficacy and safety of vandetanib as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
9. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
作者: Dedong Cao.;Wei Ge.;Huimin Wang.;Ling Zhang.;Yongfa Zheng.;Jinzhong Zhang.
来源: Zhongguo Fei Ai Za Zhi. 2011年14卷5期404-13页
In recent years, there has been a large number of studies and reports about the efficacy and safety of recombinant human endostatin (rh-endostatin), an anti-angiogenic drug, in treatment of advanced lung cancer. Authentic assessment of rh-endostatin treatment in lung cancer is important. The aim of this study is to assess the clinical efficacy and safety of rh-endostatin combined with chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC).
10. [Gefitinib for non-small cell lung cancer: a meta analysis].
作者: Jiwu Guo.;Bin Ma.;Huiyin Zhou.;Yao Wang.;Yuan Zhang.
来源: Zhongguo Fei Ai Za Zhi. 2011年14卷4期351-7页
Malignant grade and death rate are very high for non-small cell lung cancer, and gefitinib is a new molecule target anticancer drug. The aim of this meta analysis is to evaluate the clinical efficacy and safety of gefitinib for non-small cell lung cancer.
11. [A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].
作者: Jin Jiang.;Lun Li.;Xiaojing Wang.;Jinhui Tian.;Quan Wang.;Qiao Lin.
来源: Zhongguo Fei Ai Za Zhi. 2011年14卷1期43-8页
Whether pemetrexed plus platinum (PP) regimen is superior to gemcitabine plus platinum (GP) regimen for patients with advanced non-small cell lung cancer (NSCLC) is unclear. The aim of this study is to evaluate the efficacy and safety of PP versus GP regimens for patients with NSCLC.
12. [A meta-analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting].
To assess the efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) after moderately or highly emetogenic chemotherapy.
13. [A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].
作者: Yunjiu Gou.;Lingjuan Zhang.;Qimei Yang.;Rongfang Zhang.;Huiling Guo.;Lei Jiang.;Kehu Yang.;Jinhui Tian.
来源: Zhongguo Fei Ai Za Zhi. 2010年13卷3期216-23页
Whether gemcitabine plus platinum chemotherapy is superior to gemcitabine or platinum single-agent chemotherapy for patients with non-small cell lung cancer (NSCLC) is still in dispute, and the aim of this study is to evaluate the efficacy and safety of gemcitabine combining platinum chemotherapy for patients with NSCLC.
14. [Efficacy and safety in treatment of ocular neovascularization by Bevacizumab versus Ranibizumab: a meta-analysis].
To evaluate the efficacy and safety in treatment of ocular neovascularization by Bevacizumab versus Ranibizumab.
15. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
作者: De-Rong Xie.;Han-Lin Liang.;Qiong Yang.;Shuang-Shuang Guo.;Zhi-Min Jiang.
来源: Ai Zheng. 2007年26卷8期895-9页
Recent clinical trials showed that gemcitabine (GEM) of fixed-dose rate infusion has certain effect on advanced pancreatic cancer. Some meta-analyses suggest that GEM plus cisplatin (DDP) or its analogues is better than GEM alone in treating advanced pancreatic cancer. This study was to evaluate the efficacy of GEM of fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as first-line therapy for advanced pancreatic cancer by meta-analysis.
|